JP2009543802A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543802A5
JP2009543802A5 JP2009519653A JP2009519653A JP2009543802A5 JP 2009543802 A5 JP2009543802 A5 JP 2009543802A5 JP 2009519653 A JP2009519653 A JP 2009519653A JP 2009519653 A JP2009519653 A JP 2009519653A JP 2009543802 A5 JP2009543802 A5 JP 2009543802A5
Authority
JP
Japan
Prior art keywords
nrr
nhr
acyl
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009519653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543802A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/073285 external-priority patent/WO2008008854A2/en
Publication of JP2009543802A publication Critical patent/JP2009543802A/ja
Publication of JP2009543802A5 publication Critical patent/JP2009543802A5/ja
Pending legal-status Critical Current

Links

JP2009519653A 2006-07-11 2007-07-11 医学的疾患の治療のためのジアジン及びトリアジン構造を含むcxcr4アンタゴニスト Pending JP2009543802A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83000606P 2006-07-11 2006-07-11
US81999706P 2006-07-11 2006-07-11
PCT/US2007/073285 WO2008008854A2 (en) 2006-07-11 2007-07-11 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders

Publications (2)

Publication Number Publication Date
JP2009543802A JP2009543802A (ja) 2009-12-10
JP2009543802A5 true JP2009543802A5 (https=) 2011-09-01

Family

ID=38924159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519653A Pending JP2009543802A (ja) 2006-07-11 2007-07-11 医学的疾患の治療のためのジアジン及びトリアジン構造を含むcxcr4アンタゴニスト

Country Status (4)

Country Link
US (1) US8080659B2 (https=)
EP (1) EP2041067A4 (https=)
JP (1) JP2009543802A (https=)
WO (1) WO2008008854A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006203826A1 (en) * 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
AU2009228034A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
WO2011094389A2 (en) * 2010-01-27 2011-08-04 Emory University Cxcr4 antagonists for imaging of cancer and inflammatory disorders
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
WO2013070660A1 (en) * 2011-11-07 2013-05-16 Emory University Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
PT2794626T (pt) 2011-12-22 2018-01-12 Glycomimetics Inc Compostos de antagonistas de e-selectina
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
EP3152226B1 (en) 2014-06-06 2019-05-29 Technische Universität München Modified cyclopentapeptides and uses thereof
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
US10434195B2 (en) * 2015-08-03 2019-10-08 Emory University Methylsulfonamide derivatives and uses related thereto
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
WO2019173229A1 (en) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
WO2020198026A1 (en) * 2019-03-22 2020-10-01 Yumanity Therapeutics, Inc. Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US776465A (en) * 1904-04-15 1904-11-29 Charles A Gildemeyer Spigot.
US5993817A (en) * 1995-01-23 1999-11-30 Xenotech Method to ameliorate osteolysis and metastasis
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
AU6390696A (en) 1995-06-20 1997-01-22 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, nd their uses
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5874438A (en) * 1996-10-11 1999-02-23 Bayer Aktiengesellschaft 2,2'-bridged bis-2,4-diaminoquinazolines
WO1999028474A2 (en) * 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6420354B1 (en) * 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
CA2319142A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
EP1050583A4 (en) * 1998-11-24 2005-02-02 Hisamitsu Pharmaceutical Co INHIBITORS OF HIV INFECTIONS
BR0010655A (pt) * 1999-03-24 2002-02-13 Anormed Inc Compostos heterocìclicos para ligação ao receptor de quimiocina
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
WO2001038352A2 (en) 1999-11-24 2001-05-31 Schering Corporation Methods of inhibiting metastasis
CA2369056A1 (en) 2000-02-03 2001-08-09 Thomas Jefferson University Vmip-ii peptide antagonists of cxcr4
AU2001248365A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
WO2002002516A2 (en) * 2000-06-30 2002-01-10 Thomas Jefferson University Inhibitors of hiv integrase
WO2002094261A1 (fr) 2001-05-24 2002-11-28 Kureha Chemical Industry Company, Limited Medicaments antagonistes de cxcr4 comprenant un compose contenant de l'azote
US20040254221A1 (en) * 2001-09-28 2004-12-16 Toru Yamazaki Novel Nitrogenous Compound and use thereof
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Cxcr4拮抗薬およびその用途
DE10240064A1 (de) 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
US20040132642A1 (en) * 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
JP2006524242A (ja) 2003-03-27 2006-10-26 エモリー ユニバーシティー Cxcr4アンタゴニストおよびそれらの使用方法
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ES2501169T3 (es) * 2003-11-24 2014-10-01 Prometic Biosciences Inc. Dímeros de triazina para el tratamiento de enfermedades autoinmunitarias
GB0405193D0 (en) * 2004-03-08 2004-04-21 Medical Res Council Compounds
WO2006074428A2 (en) 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of medical disorders
AU2006203826A1 (en) * 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
US20080227799A1 (en) * 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders

Similar Documents

Publication Publication Date Title
JP2009543802A5 (https=)
JP2018158926A5 (https=)
JP2009502743A5 (https=)
JP2016506916A5 (https=)
JP2010524932A5 (https=)
JP2014193925A5 (https=)
JP2014508804A5 (https=)
JP2008525416A5 (https=)
JP2015505296A5 (https=)
JP2005523922A5 (https=)
JP2013518107A5 (https=)
JP2016514192A5 (https=)
JP2009536221A5 (https=)
JP2008539267A5 (https=)
JP2013507423A5 (https=)
JP2010077141A5 (https=)
JP2012519691A5 (https=)
JP2013544276A5 (https=)
JP2013544799A5 (https=)
JP2015529228A5 (https=)
JP2012506872A5 (https=)
JP2017528475A5 (https=)
JP2009541225A5 (https=)
JP2009500423A5 (https=)
JP2012522841A5 (https=)